Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
Evidence that HxkC, an Aspergillus nidulans mitochondrial hexokinase-like protein, is anti-apoptotic
v
Margaret E. Katz1, Rebecca Buckland1,
and Matthias Brock2,2011
NULL
n/a
-
v
David Cánovas*, Yazmid Reyes-Domínguez#, Ana T.
Marcos*, Ulrich Güldener‡, and Joseph Strauss2011
21)
n/a
-
v
Ayumi Ohba , Kiminori Shimizu , Takahiro Shintani ,
Susumu Kawamoto , Katsuya Gomi2011
20)
n/a
-
v
Markus Gressler1, Christoph Zaehle2, Kirstin
Scherlach2, Christian Hertweck2, and Matthias Brock12011
NULL
n/a
-
v
Robbert Damveld 1, Brenda Vonk 1, Cees Sagt 1, Hildegard
Menke 1, Thibaut Wenzel2011
NULL
n/a
-
v
Downes, Damien J. , Brendan
1,2
L. Taig , Sara Lewis , Richard B. Todd , Meryl A. Davis2011
17)
n/a
-
v
Richard B. Todd , Cameron C. Hunter , Kendra S. Siebert , Koon Ho Wong , Sara Lewis , Damien J. Downes , James A. Fraser , Michael J. Hynes and
Meryl A. Davis2011
16)
n/a
-
v
Sharon Marie Garrido , Noriyuki Kitamoto , Akira
1 2
Watanabe , Takahiro Shintani , and Katsuya Gomi2011
15)
n/a
-
v
Ana T. Marcos*, Thorsten Schinko#, Joseph Strauss#, David Cánovas
2011
14)
n/a
-
v
Diane O. Inglis , Martha B. Arnaud , Jon Binkley , Gustavo Cerqueira , Maria C. Costanzo , Marcus C. Chibucos
1 1 1 2 1
, Jonathan Crabtree , Joshua Orvis , Prachi Shah , Marek S. Skrzypek , Gail Binkley , Stuart R. Miyasato , Jennifer R. Wor2011
13)
n/a